Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Venetoclax in Lymphoid Malignancies: New Insights, More to Learn.

Literature DB >> 31614111

Venetoclax in Lymphoid Malignancies: New Insights, More to Learn.

Abstract

In this issue of Cancer Cell, Guièza et al. describe that overexpression of the pro-survival protein MCL1 and cellular energy metabolic reprogramming can contribute to resistance to the BCL2 inhibitor venetoclax in patients with chronic lymphocytic leukemia. This adds a new dimension to understanding of secondary clinical resistance to venetoclax.

Entities: Disease Gene Species

Year: 2019 PMID： 31614111 DOI： 10.1016/j.ccell.2019.09.008

Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743

Keyword Cloud
Cited

8 in total

1. Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL.

Authors: Kallesh D Jayappa; Vicki L Gordon; Christopher G Morris; Briana Wilson; B Dharmaveer Shetty; Konrad J Cios; Puja C Arora; Krista M Isaac; Shekhar Saha; Timothy P Bender; Michael E Williams; Craig A Portell; Michael J Weber
Journal: Blood Adv Date: 2021-09-14

2. Ancient and conserved functional interplay between Bcl-2 family proteins in the mitochondrial pathway of apoptosis.

Authors: Nikolay Popgeorgiev; Jaison D Sa; Lea Jabbour; Suresh Banjara; Trang Thi Minh Nguyen; Aida Akhavan-E-Sabet; Rudy Gadet; Nikola Ralchev; Stéphen Manon; Mark G Hinds; Hans-Jürgen Osigus; Bernd Schierwater; Patrick O Humbert; Ruth Rimokh; Germain Gillet; Marc Kvansakul
Journal: Sci Adv Date: 2020-09-30 Impact factor: 14.136

3. A genetic predictive model for precision treatment of diffuse large B-cell lymphoma with early progression.

Authors: Jialin Ma; Zheng Yan; Jiuyang Zhang; Wenping Zhou; Zhihua Yao; Haiying Wang; Junfeng Chu; Shuna Yao; Shuang Zhao; Peipei Zhang; Yuanlin Xu; Qingxin Xia; Jie Ma; Bing Wei; Shujun Yang; Kangdong Liu; Yongjun Guo; Yanyan Liu
Journal: Biomark Res Date: 2020-08-26

Review 4. Progress in understanding the mechanisms of resistance to BCL-2 inhibitors.

Authors: Yilan Xu; Haige Ye
Journal: Exp Hematol Oncol Date: 2022-05-21

5. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.

Authors: Rachel Thijssen; Sarah T Diepstraten; Donia Moujalled; Edward Chew; Christoffer Flensburg; Melissa X Shi; Michael A Dengler; Veronique Litalien; Sarah MacRaild; Maoshan Chen; Natasha S Anstee; Boris Reljić; Sarah S Gabriel; Tirta M Djajawi; Chris D Riffkin; Brandon J Aubrey; Catherine Chang; Lin Tai; Zhen Xu; Thomas Morley; Giovanna Pomilio; Claudia Bruedigam; Axel Kallies; David A Stroud; Ashish Bajel; Ruth M Kluck; Steven W Lane; Marie Schoumacher; Sébastien Banquet; Ian J Majewski; Andreas Strasser; Andrew W Roberts; David C S Huang; Fiona C Brown; Gemma L Kelly; Andrew H Wei
Journal: Blood Date: 2021-05-20 Impact factor: 22.113

Venetoclax in Lymphoid Malignancies: New Insights, More to Learn.

1. Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL.

2. Ancient and conserved functional interplay between Bcl-2 family proteins in the mitochondrial pathway of apoptosis.

3. A genetic predictive model for precision treatment of diffuse large B-cell lymphoma with early progression.

Review 4. Progress in understanding the mechanisms of resistance to BCL-2 inhibitors.

5. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.

Review 6. Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance.

Review 7. Review of Venetoclax in CLL, AML and Multiple Myeloma.

8. The anti-apoptotic Bcl-2 protein regulates hair follicle stem cell function.